What’s happening in peptides
Regulation, approvals, warning letters and research milestones, reported as news and linked to the guides that go deeper.
What this is about
Peptide World runs two things side by side. This page is the fast half.
Fast, current, sourced
What happened this week in regulation, approvals and research. Written by our editorial team, checked against primary sources, published quickly. Not clinically reviewed.
Deep, evidence-graded, reviewed
Our evergreen library: every claim graded for evidence strength, reviewed by the Medical Advisory Board on a rolling basis. When news raises a question, the guides answer it properly.
Can you legally get these peptides?
The six peptides an FDA advisory committee backed in July 2026, plus the one it rejected. “Compounding” means a licensed pharmacy may prepare a drug on prescription. Until the FDA formally adds a substance to its 503A list, that route stays closed, whatever a seller claims. We update this table with every step.
| Peptide | Legal to compound today | Latest step |
|---|---|---|
| BPC-157 | Not yet | FDA advisers recommended it, 8–6. Agency decision pending. |
| TB-500 | Not yet | FDA advisers recommended it, 8–6. Agency decision pending. |
| KPV | Not yet | FDA advisers recommended it, 8–6. Agency decision pending. |
| MOTS-c | Not yet | FDA advisers recommended it, 7–5. Agency decision pending. |
| Epitalon | Not yet | FDA advisers recommended it, 7–4. Agency decision pending. |
| Semax | Not yet | FDA advisers recommended it, 8–5. Agency decision pending. |
| Emideltide (DSIP) | No | FDA advisers voted against it, 6–7. |
How we got here: April 15, the FDA moved twelve peptides out of its “significant safety concerns” category · May 14, the interim list was republished · July 23–24, the advisory committee recommended six of seven peptides · still open: the formal FDA decision, with no announced date.
Latest news
Every story checked against primary sources and linked to the guide that explains the background.
Ozempic is a pill now: what the oral semaglutide shake-up means
Novo Nordisk retired the Rybelsus name, launched higher-bioavailability Ozempic tablets, and brought a 25 mg oral Wegovy to weight management. The injection era is getting company.